Perrier L

References (3)

Title : The Rosa genome provides new insights into the domestication of modern roses - Raymond_2018_Nat.Genet_50_772
Author(s) : Raymond O , Gouzy J , Just J , Badouin H , Verdenaud M , Lemainque A , Vergne P , Moja S , Choisne N , Pont C , Carrere S , Caissard JC , Couloux A , Cottret L , Aury JM , Szecsi J , Latrasse D , Madoui MA , Francois L , Fu X , Yang SH , Dubois A , Piola F , Larrieu A , Perez M , Labadie K , Perrier L , Govetto B , Labrousse Y , Villand P , Bardoux C , Boltz V , Lopez-Roques C , Heitzler P , Vernoux T , Vandenbussche M , Quesneville H , Boualem A , Bendahmane A , Liu C , Le Bris M , Salse J , Baudino S , Benhamed M , Wincker P , Bendahmane M
Ref : Nat Genet , 50 :772 , 2018
Abstract : Roses have high cultural and economic importance as ornamental plants and in the perfume industry. We report the rose whole-genome sequencing and assembly and resequencing of major genotypes that contributed to rose domestication. We generated a homozygous genotype from a heterozygous diploid modern rose progenitor, Rosa chinensis 'Old Blush'. Using single-molecule real-time sequencing and a meta-assembly approach, we obtained one of the most comprehensive plant genomes to date. Diversity analyses highlighted the mosaic origin of 'La France', one of the first hybrids combining the growth vigor of European species and the recurrent blooming of Chinese species. Genomic segments of Chinese ancestry identified new candidate genes for recurrent blooming. Reconstructing regulatory and secondary metabolism pathways allowed us to propose a model of interconnected regulation of scent and flower color. This genome provides a foundation for understanding the mechanisms governing rose traits and should accelerate improvement in roses, Rosaceae and ornamentals.
ESTHER : Raymond_2018_Nat.Genet_50_772
PubMedSearch : Raymond_2018_Nat.Genet_50_772
PubMedID: 29713014
Gene_locus related to this paper: rosch-a0a2p6p237 , rosch-a0a2p6r1h5 , rosch-a0a2p6saq0 , rosch-a0a2p6sap4 , rosch-a0a2p6san0 , rosch-a0a2p6san7 , rosch-a0a2p6rkg2 , rosch-a0a2p6pxu1 , rosch-a0a2p6s382 , rosch-a0a2p6s367 , rosch-a0a2p6q0b7 , rosch-a0a2p6pi87 , rosch-a0a2p6p278 , rosch-a0a2p6s545 , rosch-a0a2p6r6x5 , rosch-a0a2p6rqc2

Title : Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis - Tricco_2018_J.Am.Geriatr.Soc_66_170
Author(s) : Tricco AC , Ashoor HM , Soobiah C , Rios P , Veroniki AA , Hamid JS , Ivory JD , Khan PA , Yazdi F , Ghassemi M , Blondal E , Ho JM , Ng CH , Hemmelgarn B , Majumdar SR , Perrier L , Straus SE
Ref : J Am Geriatr Soc , 66 :170 , 2018
Abstract : BACKGROUND/OBJECTIVES: To examine the comparative effectiveness and safety of cognitive enhancers for Alzheimer's disease (AD). DESIGN: Systematic review and Bayesian network metaanalysis (NMA). SETTING: MEDLINE, EMBASE, Cochrane Library, CINAHL, Ageline (inception-March 2016). PARTICIPANTS: Individuals with AD in randomized controlled trials (RCTs), quasi-RCTs, and nonrandomized studies. INTERVENTION: Any combination of donepezil, rivastigmine, galantamine, or memantine. MEASUREMENTS: Two reviewers independently screened titles, abstracts, and full-texts; abstracted data; and appraised risk of bias. RESULTS: Twenty thousand three hundred forty-three citations were screened, and 142 studies were included (110 RCTs, 21 non-RCTs, 11 cohort studies). NMA found that donepezil (Mini-Mental State Examination: mean difference (MD) = 1.39, 95% credible interval (CrI) = 0.53-2.24), donepezil+memantine (2.59, 95% CrI = 0.12-4.98), and transdermal rivastigmine (2.02, 95% CrI = 0.02-4.08) improved cognition more than placebo. NMA found that donepezil (Alzheimer's Disease Assessment Scale-cognitive: MD = -3.29, 95% CrI = -4.57 to -1.99) and galantamine (MD = -2.13, 95% CrI = -3.91 to -0.27) improved cognition more than placebo. NMA found that donepezil+memantine (MD = -5.23, 95% CrI = -8.72 to -1.56) improved behavior more than placebo. NMA found that donepezil (MD = -0.32, 95% CrI = -0.46 to -0.19), donepezil+memantine (MD = -0.57, 95% CrI = -0.95 to -0.21), oral rivastigmine (MD = -0.38, 95% CrI = -0.56 to -0.17), and galantamine (MD = -3.79, 95% CrI = -6.98 to -0.59) improved global status more than placebo. NMA found that galantamine decreased the odds of mortality (odds ratio = 0.56, 95% CrI = 0.36-0.87). No agent increased risk of serious adverse events, falls, or bradycardia. Some increased risk of headache (oral rivastigmine), diarrhea (oral rivastigmine, donepezil), nausea (oral rivastigmine, donepezil, galantamine), and vomiting (oral rivastigmine, donepezil, galantamine). CONCLUSION: An exhaustive review of the literature involving 142 studies demonstrated that cognitive enhancers in general have minimal effects on cognition according to minimal clinically important difference and global ratings. The drugs appear safe, but this must be interpreted cautiously because trial participants may have less comorbidity and fewer adverse effects than those treated with these drugs in clinical practice.
ESTHER : Tricco_2018_J.Am.Geriatr.Soc_66_170
PubMedSearch : Tricco_2018_J.Am.Geriatr.Soc_66_170
PubMedID: 29131306

Title : Efficacy of cognitive enhancers for Alzheimer's disease: protocol for a systematic review and network meta-analysis - Tricco_2012_Syst.Rev_1_31
Author(s) : Tricco AC , Vandervaart S , Soobiah C , Lillie E , Perrier L , Chen MH , Hemmelgarn B , Majumdar SR , Straus SE
Ref : Syst Rev , 1 :31 , 2012
Abstract : BACKGROUND: Approximately 35 million people world-wide have Alzheimer's disease and this is projected to nearly double by 2030. Cognitive enhancers, including cholinesterase inhibitors (for example, donepezil, galantamine and rivastigmine) and memantine (N-methyl-D-aspartic acid (NMDA) receptor antagonist) have been approved for the treatment of Alzheimer's disease in many countries. Our objective is to evaluate the comparative effectiveness, safety, and cost of cognitive enhancers for Alzheimer's disease through a systematic review. METHODS/DESIGN: Studies examining the efficacy, safety, and cost of cognitive enhancers compared to placebo, supportive care, and other cognitive enhancers for Alzheimer's patients will be included. The primary outcome is cognition and secondary outcomes include function, behavior, quality of life, safety, and cost. Experimental studies (randomized controlled trials, quasi-randomized controlled trials, controlled clinical trials), quasi-experimental studies (controlled before-after, interrupted time series), and observational studies (cohort, case-control studies) will be eligible for inclusion. Inclusion will not be limited by publication status, time period or language of dissemination.We will search electronic databases (for example, MEDLINE, Cochrane Central Register of Controlled Trials, EMBASE, CINAHL, Ageline) from inception onwards. The electronic database search will be supplemented by searching for grey literature (for example, conference proceedings, searches in Google and relevant organization websites). Two reviewers will independently screen the studies for inclusion using the eligibility criteria established a priori and independently extract data. Risk of bias will be assessed using the Cochrane Risk of Bias tool for experimental and quasi-experimental studies and the Newcastle Ottawa Scale for observational studies. If deemed appropriate, meta-analysis and network (that is, indirect comparisons) meta-analysis will be conducted. DISCUSSION: Our systematic review will inform the decision of healthcare providers, policy-makers, Alzheimer's patients and family members about the use of cognitive enhancers, by improving their understanding of the costs, benefits and harms that are associated with these agents. PROSPERO REGISTRY NUMBER: CRD42012001948.
ESTHER : Tricco_2012_Syst.Rev_1_31
PubMedSearch : Tricco_2012_Syst.Rev_1_31
PubMedID: 22742585